NorthWest Biotherapeutics Inc (NWBO)

[HyGro]

Trials need to offer a rescue to assist in recruiting -- a patient getting an experimental treatment wants assurance they will have a rescue option if it fails.

From the trial protocol filed on clinicaltrials.gov:
"All patients will have the option to receive DCVax-L in a crossover arm upon documented disease progression. "

So DCVax-L was the only other option NWBO was offering other than leaving the trial.